These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35917650)

  • 21. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
    Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
    J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
    J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.
    Noroozian M; Ghasemi S; Hosseini SM; Modabbernia A; Khodaie-Ardakani MR; Mirshafiee O; Farokhnia M; Tajdini M; Rezaei F; Salehi B; Ashrafi M; Yekehtaz H; Tabrizi M; Akhondzadeh S
    Psychopharmacology (Berl); 2013 Aug; 228(4):595-602. PubMed ID: 23515583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.
    Hirschfeld RM; Eerdekens M; Kalali AH; Canuso CM; Khan AA; Karcher K; Palumbo JM
    Int Clin Psychopharmacol; 2006 Jan; 21(1):11-20. PubMed ID: 16317312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
    Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M
    J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
    Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL
    Am J Psychiatry; 2002 Jul; 159(7):1146-54. PubMed ID: 12091192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
    Akhondzadeh S; Tabatabaee M; Amini H; Ahmadi Abhari SA; Abbasi SH; Behnam B
    Schizophr Res; 2007 Feb; 90(1-3):179-85. PubMed ID: 17208413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.
    Akhondzadeh S; Ghayyoumi R; Rezaei F; Salehi B; Modabbernia AH; Maroufi A; Esfandiari GR; Naderi M; Ghebleh F; Tabrizi M; Rezazadeh SA
    Psychopharmacology (Berl); 2011 Feb; 213(4):809-15. PubMed ID: 20949350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
    Iranpour N; Zandifar A; Farokhnia M; Goguol A; Yekehtaz H; Khodaie-Ardakani MR; Salehi B; Esalatmanesh S; Zeionoddini A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Hum Psychopharmacol; 2016 Mar; 31(2):103-12. PubMed ID: 26856695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial.
    Abdallah MS; Mosalam EM; Hassan A; Ramadan AN; Omara-Reda H; Zidan AA; Samman WA; El-Berri EI
    CNS Neurosci Ther; 2023 Jan; 29(1):354-364. PubMed ID: 36341700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR; Mirshafiee O; Farokhnia M; Tajdini M; Hosseini SM; Modabbernia A; Rezaei F; Salehi B; Yekehtaz H; Ashrafi M; Tabrizi M; Akhondzadeh S
    Psychiatry Res; 2014 Mar; 215(3):540-6. PubMed ID: 24480077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial.
    Ghanizadeh A; Dehbozorgi S; OmraniSigaroodi M; Rezaei Z
    Recent Pat Inflamm Allergy Drug Discov; 2014; 8(3):211-5. PubMed ID: 25353174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.